MktsMarkets

Viking Therapeutics, Inc.
NASDAQ: VKTXKey statistics
VKTX News
Stories mentioning VKTX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 150,150 | 153,458 | 89,953 | 60,153 | 41,391 | 30,987 | 22,785 | 23,769 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 164,125 | 164,738 | 98,561 | 74,574 | 55,469 | 46,238 | 36,556 | 34,054 |
| Operating Income (Loss) | (164,125) | (164,738) | (98,561) | (74,574) | (55,469) | (46,238) | (36,556) | (34,054) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 5,800 | 7,076 | 7,774 | 9,013 | 9,840 | 10,821 | 11,616 | 11,804 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (158,325) | (157,662) | (90,787) | (65,561) | (45,629) | (35,417) | (24,940) | (22,250) |
| Earnings Per Share (Basic) | (1.37) | (1.40) | (0.81) | (0.58) | (0.41) | (0.32) | (0.22) | (0.20) |
| Earnings Per Share (Diluted) | (1.37) | (1.40) | (0.81) | (0.58) | (0.41) | (0.32) | (0.22) | (0.20) |
| Weighted Average Shares Outstanding (Basic) | 115,568 | 112,667 | 112,320 | 112,134 | 112,069 | 109,037 | 110,911 | 110,390 |
| Weighted Average Shares Outstanding (Diluted) | 115,568 | 112,667 | 112,320 | 112,134 | 112,069 | 109,037 | 110,911 | 110,390 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About VKTX
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a stock listed on the Nasdaq Stock Market under the ticker symbol VKTX. It last traded at $26.17 (Nov 18, 2026, 4:00 PM ET), down 2.6% on the day. That gives Viking Therapeutics a market capitalisation of $3.4B.
Over the past 52 weeks VKTX has traded between $23.82 and $43.10.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $158.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$158.3M |
| Dec 31, 2025 | $0 | -$157.7M |
| Sep 30, 2025 | $0 | -$90.8M |
| Jun 30, 2025 | $0 | -$65.6M |
From Viking Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…